OTCMKTS:ZLDPF

Zealand Pharma A/S Q1 2025 Earnings Results & Report

Zealand Pharma A/S logo
$35.93 0.00 (0.00%)
As of 11/16/2026 12:02 PM Eastern

Zealand Pharma A/S beat analyst earnings expectations but missed on revenue in its Q1 2025 results, released May 8, 2025. The company reported EPS of -$0.67 versus the -$0.77 consensus estimate, while revenue of $1.14 million fell short of the $248.61 million estimate by $247.47 million.

Earnings Announcement Details

Quarter
Q1 2025
Report Date
Time
Before Market Opens

Zealand Pharma A/S EPS Results

Actual EPS
-$0.67
Consensus EPS
-$0.77
Beat/Miss
Beat by +$0.10
One Year Ago EPS
N/A
EPS Beat Rate
6 of last 8 quarters

Zealand Pharma A/S Revenue Results

Actual Revenue
$1.14 million
Expected Revenue
$248.61 million
Beat/Miss
Missed by -$247.47 million
YoY Revenue Growth
N/A

Conference Call Resources

Zealand Pharma A/S Q1 2025 Earnings FAQ

Zealand Pharma A/S (OTCMKTS:ZLDPF) reported earnings of -$0.67 per share for Q1 2025, beating the consensus estimate of -$0.77. The report was announced on Thursday, May 8, 2025.

Zealand Pharma A/S reported revenue of $1.14 million for Q1 2025, against a consensus estimate of $248.61 million.

Zealand Pharma A/S Earnings Headlines

Zealand Pharma Earnings Call Signals Strong Pipeline Momentum
Your book is inside
The "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. They don't know the rules. They don't know what to avoid. And they hand their account to Wall Street on a silver platter. Normally $29.97. Free today.tc pixel
Zealand Pharma A/S Q3 Loss Declines
See More Zealand Pharma A/S Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Zealand Pharma A/S? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Zealand Pharma A/S and other key companies, straight to your email.

About Zealand Pharma A/S

Zealand Pharma A/S (OTCMKTS:ZLDPF) is a biotechnology company headquartered in Copenhagen, Denmark. Founded in 1998, it discovers and develops peptide-based medicines, with a focus on metabolic diseases and rare conditions.

The company’s portfolio has included Zegalogue (dasiglucagon), an injectable treatment approved in the United States for severe hypoglycemia in people with diabetes. Zealand also develops investigational medicines for areas such as obesity, liver disease and rare gastrointestinal disorders, and works with pharmaceutical partners to advance and commercialize selected programs.

Zealand Pharma serves international markets through its development and commercial partnerships. Adam Steensberg has served as the company’s president and chief executive officer.

View Zealand Pharma A/S Profile